Identification of structural aberrations in cancer by SNP array analysis by Heinrichs, Stefan & Look, A Thomas
Genome Biology 2007, 8:219
Minireview
Identification of structural aberrations in cancer by SNP array
analysis
Stefan Heinrichs and A Thomas Look
Address: Dana-Farber Cancer Institute, Department of Pediatric Oncology, Binney Street, Boston, MA 02215, USA.
Correspondence: A Thomas Look. Email: thomas_look@dfci.harvard.edu
Abstract
Recent studies using single-nucleotide polymorphism arrays have pinpointed novel oncogenes and
tumor suppressors involved in specific types of human cancers.
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One of the most daunting, though rewarding, challenges in
cancer medicine is to determine how specific genetic
alterations in tumors may affect the prognosis and lead to
targeted therapies for the individual cancer patient. Current
methods of gene-expression profiling have revealed that
tumor types previously thought to be homogenous from
histological criteria alone often have different underlying
molecular signatures [1-3]. Complex mutational events seem
to have a major impact on the expression of specific genes
that contribute to the induction and progression of cancer,
and, therefore, on the aggressiveness of the tumor and the
clinical outcome of therapy [3-5]. The precise assessment of
tumor-cell heterogeneity has thus become a central focus of
cancer investigations. The ultimate goal of these efforts is to
identify disease subtypes that are driven by altered signaling
pathways whose genetic defects correlate well with
prognosis and that offer attractive targets for molecular
intervention [6-11].
The longest-established method of diagnosing and differen-
tiating tumor types is the detection of chromosomal
aberrations by cytogenetic analysis. Molecular cytogenetic
techniques, such as spectral karyotyping, fluorescence in situ
hybridization and chromosome-based comparative genomic
hybridization (CGH), substantially improved resolution and
genome coverage compared with conventional cytogenetics.
But these techniques still did not offer the resolution and
genome coverage of microarray gene-expression profiling.
This can provide clinically significant insights into the
heterogeneity of tumor cells and has been used to subclassify
various human tumors [1-3,12], but it can sometimes be
difficult to identify the truly relevant genes among the
multiplicity of differences in gene expression recorded.
Genomic methods that identify mutations directly and cover
the whole genome at a similarly high resolution are required
to help resolve such problems.
One attempt to improve the detection of structurally altered
genomic regions combines classic CGH with the microarray
platform, generating the array CGH technique, which relies
on competitive hybridization of fragmented, labeled tumor
DNA together with fragmented, but differentially labeled
control DNA [13,14]. The microarray platform facilitates
higher-resolution mapping of genomic regions that contain
copy-number aberrations, such as amplifications and
deletions, and the interpretation of data from array CGH
studies is much more straightforward than that of conven-
tional CGH. Another new microarray-based cytogenetic
technique, high-resolution single-nucleotide polymorphism
(SNP) array analysis, perhaps holds even greater promise for
detailed structural examination of the cancer genome. SNP
arrays allow the high resolution detection of loss of hetero-
zygosity, a common event in tumorigenesis, in addition to
the identification of DNA copy-number aberrations at a
resolution similar to that of array CGH. A recent study of
childhood acute lymphoblastic leukemia (ALL) by Mullighan
et al. [15] illustrates the strength of SNP arrays for the
identification of key genetic abnormalities in cancer.Advantages of SNP array analysis
A SNP is defined as a DNA sequence variation at one specific
position in the genome that occurs in at least 1% of the
human population. Almost all SNPs have only two alleles,
and so the heterozygous genotype and the two types of
homozygous genotypes can generally be unambiguously
determined. On current microarray platforms, 300,000 to
500,000 SNPs can be genotyped simultaneously. Ideally, the
tumor sample is analyzed in parallel with a normal - or
‘germline’ - sample from the same patient; if such a control
sample is unavailable, algorithms can be used instead [16].
However, with this approach, the resolution will be lowered,
and the data interpretation could be hampered due to the
extensive somatic variation in copy number within human
populations (so-called copy number variation, or CNV) [17].
As the signal obtained for each position on the array is
quantitative, DNA copy number can be determined from it.
At the same time, a discrete genotype designation is
generated that can be used to detect regions of loss of
heterozygosity by comparison with the patient’s germline
DNA. Loss of heterozygosity means the loss of one allele at a
given position (or positions); it is classically associated with
tumorigenesis when a ‘good’ copy of a tumor suppressor
gene is physically lost as a result of the deletion of a
chromosome or a chromosomal region, leaving the cancer
cell with only one (usually defective) allele.
Copy-number analysis by comparison to a matched normal
DNA control for each patient’s tumor will rapidly detect gene
amplification, low-copy gain and deletion with a high degree
of confidence, even at the level of a single-copy gain or loss
(Figure 1). To identify regions of loss of heterozygosity, one
must infer genotype calls from a string of adjacent hetero-
zygous SNPs, because homozygous germline genotypes are
noninformative.
Most commonly, the loss of heterozygosity in tumor cells is a
result of deletion of a region of a chromosome or of a whole
chromosome, and SNP arrays identify these deleted regions
as having loss of heterozygosity combined with a copy-
number reduction. Loss of heterozygosity can, however,
appear without a copy-number change - copy-neutral loss of
heterozygosity. For example, a mutated tumor suppressor
allele and its surrounding DNA can be copied and replace the
other allele by somatic homologous recombination during the
development of the neoplastic clone, resulting in a tumor cell
that is homozygous for the mutated tumor suppressor allele
and has a growth or survival advantage. This type of
mutational event is known as uniparental disomy (UPD) and
represents an important but largely overlooked mechanism
for generating loss of heterozygosity. One of the advantages
of SNP microarrays is that they are unique among genomic
analysis methods in being able to identify UPD.
The study by Mullighan et al. [15] nicely illustrates the
advantages of SNP arrays. The authors analyzed 192 cases of
pediatric B-cell-progenitor acute lymphoblastic leukemia
(B-ALL), 94% of which had a matched control sample from a
time when the patient’s leukemia was in remission.
Recurrent chromosomal abnormalities are a hallmark of
early B-ALL and the karyotype is, therefore, used to classify
subtypes of the disease [18]. Copy-number analysis of the
B-ALL cases by Mullighan et al. [15] revealed an overall
prevalence of deletions in all subgroups except the
hyperdiploid cases (cases with more than 50 chromosomes
in the leukemic clone), in which gains dominated.
The highest frequency of deletions was found in hypodiploid
cases (cases with less than 45 chromosomes in the leukemic
clone), and in cases in which the ETV6 gene (on chromo-
some 12) and the RUNX1  gene (on chromosome 21; both
genes encode transcription factors) were fused as the result
of a translocation. A deletion involving ETV6 was detected in
33 of 46 cases also harboring this translocation between
chromosomes 12 and 21. By contrast, cases with rearrange-
ments affecting the MLL gene had a very low frequency of
deletions and almost no amplifications. Altogether, the study
identified more than 40 regions that were recurrently
deleted in different patients, with three focal segments of
chromosome 9 showing the highest overall frequency of
deletions. At 9p21.3, a third of all cases had deletions in the
tumor suppressor locus CDKN2A (encoding both p14-ARF
and p16-INK4A), often occuring in the context of a region of
UPD. A fifth of cases had a deleted MLL translocation
partner gene MLLT3 (AF9), located on 9p21. More than a
quarter of the cases (56 of 192) showed a deletion at 9p13.2,
a locus not previously identified as being involved in B-ALL.
Some informative cases had very focused deletions that
pinpointed the PAX5 gene as the likely target on chromo-
some band 9p13.2 [15]. Indeed, sequencing and functional
studies by Mullighan et al. [15] led to the identification of
PAX5 as a highly tumor type-specific tumor suppressor gene
in early B-cell lineage ALL. PAX5 encodes a transcription
factor that drives the differentiation of progenitor B cells by
repressing self-renewal programs and activating genes
specific for the B-cell lineage [19]. Mullighan et al. [15]
found that haploinsufficiency rather than total loss of PAX5
function predominated; the deletions were accompanied by
mutation of the remaining allele in only a minority of cases and
two cases were identified that had a heterozygous mutation
without a deletion. Other genes involved in B-cell development
were found to be deleted in some cases, including EBF1, a
transcription factor obligatory for B-progenitor cell differen-
tiation. Six of eight cases showed very focused deletions that
affected only the EBF1 locus and, therefore, were not
detectable by conventional cytogenetic analysis.
The identification of PAX5 and  EBF1 as new mutational
targets in early B-lineage leukemogenesis shows the value
of SNP array studies for selecting genes for detailed
analysis. Like PAX5, the EBF1 gene retained one wild-type
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Figure 1
Illustration of SNP array analysis by example of matched neuroblastoma samples using the dChip software [25,26]. Normal (N) and tumor (T) DNA of
five selected patients were hybridized to 10K Affymetrix SNP arrays (data kindly provided by R George [22]). (a) Copy numbers are shown as shades of
red. Sample 1, 2 and 3 show a copy-number loss on 11q, whereas samples 4 and 5 are normal. (b) The inferred comparison of the genotype (loss of
heterozygosity (LOH) analysis) results in a single lane per case, in which regions of LOH are depicted in blue and heterozygous regions are in yellow.
Besides classical LOH with copy-number loss (11q region of samples 1-3), a region of UPD, identified by copy-neutral LOH, is identified in sample 3 on
11p. (c) The actual genotype calls for the UPD region and part of the adjacent region of sample 3 are shown in expanded form. The region of UPD
shows only red (A) or blue (B) SNP calls, whereas other regions have the expected numbers of retained heterozygous alleles resulting in an AB call
(yellow).
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11qallele in the majority of the cases, supporting the idea that
haploinsufficiency is an inherent property of some tumor
suppressors [20,21]. In cases with defects in such genes, it
may be possible to increase gene expression from the
remaining allele.
Other work has also shown the power of SNP array analysis
to identify the loss of functional tumor suppressors even in
cases lacking chromosomal deletions, or gain of regions
containing potential oncogenes. We have performed a
matched control study by SNP array of 22 neuroblastoma
patients [22] and identified chromosomal aberrations that
had been previously implicated in neuroblastoma by more
laborious analysis of loss of heterozygosity at individual loci.
A subset of four cases showed loss of heterozygosity of 11p
solely as a result of UPD, indicating that cells might not
tolerate the haploinsufficiency generated by large deletions
of some chromosomal regions. A matched control study of
14 basal cell carcinomas by Teh et al. [23] revealed that, in
almost all cases, the region on chromosome 9q harboring the
tumor suppressor gene PTCH1  has undergone loss of
heterozygosity. More than a third of these cases resulted
from UPD, implying the duplication of a mutated allele.
Sellers and colleagues [24] have taken a different approach
to exploiting the information provided by SNP arrays. To
uncover novel signaling pathways in human cancers, they
first examined the structural genomic aberrations of a cell
line panel by SNP array copy-number analysis. Clustering of
the cell lines according to their copy-number aberrations
identified subgroups that showed amplifications and deletions
in shared regions. One cluster, comprising six out of nine
melanoma cell lines, showed a copy-number gain in a
defined region of chromosome 3p. Comparison of the gene-
expression profiles of the six melanoma cell lines with the
other lines identified a small set of genes as highly
expressed, only one of which, that encoding transcription
factor MITF, was located within the chromosome 3p region.
Additional studies established that MITF is a survival factor
with oncogenic properties in melanoma.
Thus, SNP array technology can provide a global analysis of
DNA copy-number alterations in human cancers while
revealing important loss of heterozygosity due to UPD,
which would be entirely missed by conventional cytogenetic
analysis or array CGH. Identification of UPD in tumor cells
allows genetically similar cases to be classified together for
prognostic and therapeutic purposes in the absence of a
cytogenetically apparent deletion. In addition, the finding of
a UPD implies that a significant mutational or heritable
epigenetic event has occurred within the duplicated region,
thus providing a good reason for further detailed analysis at
the DNA sequence level.
A cross comparison of all cases included in a SNP array
study makes it possible to define shared regions of
copy-number change, loss of heterozygosity and UPD and to
delineate both minimally deleted and minimally amplified
regions. Thus, SNP array studies can pinpoint critical
structurally altered regions within the genome of a particular
type of cancer and contribute to the discovery of novel
oncogenes or tumor suppressors, as shown by the study of
Mullighan  et al. [15]. The potential oncogenic function of
genes located in amplified regions that are also
overexpressed in the tumor cells can be tested functionally
in animal models.
Ultimately, SNP array analysis should provide a way to
reliably subclassify tumors on the basis of shared genetic
abnormalities, so that patients can be assigned to the most
appropriate therapies. This technology also seems especially
promising as a way of implicating oncogenic pathways and
initiating the search for targets that could be exploited in the
development of molecular therapeutics. For a protein to be a
useful therapeutic target within the cancer cell, it must have a
driving role in a pathway controlling tumor initiation, the
maintenance of the malignant phenotype or metastatic
behaviors. Tumors acquire multiple critical genetic aberra-
tions before they become clinically apparent, and, by the use
of powerful technologies, such as SNP analysis and eventually
whole genome resequencing, it should then be possible to
target several of these defects to reverse tumor growth.
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